Seagen (SGEN) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seagen Reports Third Quarter 2022 Financial Results
October 27, 2022 4:02 PM EDT-Total Revenues of $510 Million in 3Q22, Including Net Product Sales of $428 Million-
-Submitted Supplemental Biologics License Application to FDA for PADCEV in Combination with KEYTRUDA as First-Line Treatment for Advanced Urothelial Cancer-
-Announced FDA Granted Priority Review for TUKYSA in Combination with Trastuzumab for Previously Treated HER2-Positive Metastatic Colorectal Cancer-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)-- Seagen Inc. (Nasdaq: SGEN) reported financial results today for the third quarter ended September 30, 2022. The Company also highlighted PADCEV®... More
